Jan 8, 2024 Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia Learn More
Jan 3, 2024 Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 Learn More
Dec 19, 2023 Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation Learn More
Dec 12, 2023 Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform Learn More